Suzetrigine, sold under the brand name Journavx, is a medication used for the management of pain. [1] [2] It is a non-opioid, small-molecule analgesic that works as a selective inhibitor of Na v 1.8-dependent pain-signaling pathways in the peripheral nervous system, [3] [4] avoiding the addictive potential of opioids.

3 days ago · Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults.

3 days ago · Suzetrigine is a pill that’s given in two dosages. In studies, participants got an initial dose of 100 milligrams, followed by 50 milligrams every 12 hours.

Journavx (suzetrigine) is a first-in-class, oral, non-opioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that is selectively expressed in peripheral pain-sensing neurons (nociceptors), where its role is to transmit pain signals (action potentials).

3 days ago · Suzetrigine (Journavx) is a non-opioid pain medication. It’s an oral tablet that treats moderate-to-severe acute (short-term) pain in adults. This opioid alternative works by blocking pain signals from reaching the brain.

Aug 20, 2024 · In this 2024 feature, we looked at the promise of this painkiller, which blocks pain signals in peripheral nerves at or near the site of the injury. Unlike opioids (such as OxyContin), it...

3 days ago · Suzetrigine, now given the brandname Journavx, is not the first sodium channel-targeting drug to be used for pain management. Compounds such as procaine (Novocain) and lidocaine have provided ...

3 days ago · The approval of suzetrigine is “an important public health milestone in acute pain management," Jacqueline Corrigan-Curay, JD, MD, acting director of the FDA Center for Drug Evaluation and ...

3 days ago · Journavx (suzetrigine, VX-548) pain-relieving medicine (analgesic) that works by selectively blocking a ion channel called Nav1.8. It is currently undergoing investigational trials to assess its ability to relieve moderate to severe acute pain or peripheral neuropathic pain.

Jun 27, 2024 · Suzetrigine is a NaV1.8 voltage-gated sodium channel blocker with analgesic properties: It targets a pain signalling pathway in the peripheral nervous system. 1 On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic. 5